TDP‐43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP‐43 Proteinopathies
Movement Disorders · 2025-04 · 40 (4) · 662-671
DOI: 10.1002/mds.30104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 09.01.2025. Verfasst von Sarah R Pickles und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: DNA-Binding Proteins, TDP-43 Proteinopathies, Substantia Nigra, Brain. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, PPND Family Foundation, NIH HHS.
Abstract (Originalsprache)
Background
Perry syndrome (PS) is a rare and fatal hereditary autosomal dominant neurodegenerative disorder caused by mutations in dynactin ( DCTN1 ). PS brains accumulate inclusions positive for ubiquitin, transactive‐response DNA‐binding protein of 43 kDa (TDP‐43), and to a lesser extent dynactin.
Objectives
Little is known regarding the contributions of TDP‐43, an RNA binding protein that represses cryptic exon inclusion, in PS. Therefore, we sought to identify the degree of TDP‐43 dysfunction in two regions of PS brains.
Methods
We evaluated the levels of insoluble pTDP‐43 and TDP‐43‐regulated cryptic RNAs and protein in the caudate nucleus and substantia nigra of 7 PS cases, 12 cases of frontotemporal lobar degeneration (FTLD) with TDP‐43 pathology, and 11 cognitively healthy controls without TDP‐43 pathology.
Results
Insoluble pTDP‐43 protein levels were detected in PS brains to a similar extent in the caudate nucleus and substantia nigra but lower than those in FTLD brains. The caudate nucleus of PS showed accumulation of eight TDP‐43‐regulated cryptic RNAs ( ACTL6B , CAMK2B , STMN2 , UNC13A , KCNQ2 , ATG4B , GPSM2 , and HDGFL2 ) and cryptic protein (HDGFL2) characteristic of FTLD. Conversely, only one cryptic target, UNC13A , reached significance in the substantia nigra despite similar pTDP‐43 levels.
Conclusion
We detected TDP‐43 cryptic RNAs and protein in PS caudate nucleus. Given the importance of cryptic exon biology in the development of biomarkers, and the identification of novel targets for therapeutic intervention, it is imperative we understand the consequences of TDP‐43 dysfunction across different brain regions and determine the targets that are specific and common to TDP‐43 proteinopathies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
- Neurobiology of Disease Graduate Program, Mayo Graduate School, Mayo Clinic College of Medicine, Jacksonville, Florida, USA.
- Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
- Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.
- Neurology Department, St Adalbert Hospital, Copernicus PL Ltd., Gdansk, Poland.
- Department of Neurosciences, Neurology Unit, Hospital Universitario San Ignacio, Bogota, Colombia.
ORCID-Profile: Jesus Gonzalez Bejarano, Keith A Josephs, Zbigniew K Wszolek, Mercedes Prudencio
Förderung
- NINDS NIH HHS
- PPND Family Foundation
- NIH HHS
- NIA NIH HHS
- Haworth Family Professorship in Neurodegenerative Diseases fund
- BrightFocus Foundation
- Target ALS
- Vanier Canada Graduate Scholarship from the Canadian Institutes of Health Research
Zitieren
APA
Pickles, S. R., Gonzalez Bejarano, J., Narayan, A., Daughrity, L., Maroto Cidfuentes, C., Reeves, M. M., Yue, M., Castellanos Otero, P., Estades Ayuso, V., Dunmore, J., Song, Y., Tong, J., DeTure, M., Rawlinson, B., Castanedes-Casey, M., Dulski, J., Cerquera-Cleves, C., Zhang, Y., Josephs, K. A., …, & Prudencio, M. (2025). TDP‐43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP‐43 Proteinopathies. Movement Disorders, 40(4), 662-671. https://doi.org/10.1002/mds.30104
Vancouver
Pickles SR, Gonzalez Bejarano J, Narayan A, Daughrity L, Maroto Cidfuentes C, Reeves MM, et al. TDP‐43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP‐43 Proteinopathies. Movement Disorders. 2025;40(4):662-671. doi:10.1002/mds.30104
BibTeX
@article{Pickles2025,
author = {Pickles, Sarah R and Gonzalez Bejarano, Jesus and Narayan, Anand and Daughrity, Lillian and Maroto Cidfuentes, Candela and Reeves, Madison M and Yue, Mei and Castellanos Otero, Paula and Estades Ayuso, Virginia and Dunmore, Judy and Song, Yuping and Tong, Jimei and DeTure, Michael and Rawlinson, Bailey and Castanedes-Casey, Monica and Dulski, Jaroslaw and Cerquera-Cleves, Catalina and Zhang, Yongjie and Josephs, Keith A and Dickson, Dennis W and Petrucelli, Leonard and Wszolek, Zbigniew K and Prudencio, Mercedes},
title = {TDP‐43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP‐43 Proteinopathies},
journal = {Movement Disorders},
year = {2025},
volume = {40},
number = {4},
pages = {662--671},
doi = {10.1002/mds.30104}
}
EUVIMED